Photo by nci from unsplash
9571Background: Both pembrolizumab (PEMBRO) and the combination of ipilimumab and nivolumab (IPI+NIVO) are approved by the US FDA for treatment of advanced (unresectable or metastatic) melanoma. Cl... Click to show full abstract
9571Background: Both pembrolizumab (PEMBRO) and the combination of ipilimumab and nivolumab (IPI+NIVO) are approved by the US FDA for treatment of advanced (unresectable or metastatic) melanoma. Cl...
Keywords:
factors predicting;
predicting use;
advanced melanoma;
use immunotherapy;
immunotherapy patients;
patients advanced
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!